The establishment of EDCTP
The first EDCTP programme
During its first programme (EDCTP1, 2003-2015), EDCTP operated as a European Economic Interest Grouping (EEIG) incorporated in the Netherlands, with its membership restricted to 16 countries in the European Economic Area.
The EDCTP1 programme supported clinical trials on treatment drugs, vaccines, microbicides and diagnostics, focussing on HIV/AIDS, tuberculosis and malaria. The aim of the programme was to pool European resources, funding and activities to achieve a greater impact against these three poverty-related diseases, and to promote a joint approach to global health research funding among European countries. Through its funding instruments, it contributed to the coordination and cooperation among European national research programmes. A programmatic funding approach was developed that focused on clinical trials as the core activity with integrated networking and capacity development. EDCTP1 provided professional training to 514 African scientists and medical doctors, including 56 Career and Senior Fellows, as well as more than 406 Master’s and PhD students.
The EDCTP1 programme also contributed to networking African researchers, which resulted in the establishment of four African Regional Networks of Excellence for clinical research. Moreover, the ethics and regulatory environment was improved by strengthening ethics review capacity and national regulatory authorities in many African countries. EDCTP was the main funder of the African initiative to establish the Pan African Clinical Trials Registry (PACTR), which is now an official WHO Primary Clinical Trials Registry.
The second EDCTP programme
Based on the success of EDCTP1, the second EDCTP programme (EDCTP2) was launched in 2014 as another Article 185 Initiative as part of the next European Framework Programme for Research and Innovation – Horizon 2020. Read more about the Decision of the European Parliament and Council on EDCTP2.
Running until 2024, the scope of EDCTP2 is based on the objectives and achievements of EDCTP1, with an expansion to cover neglected infectious diseases, diarrhoeal diseases, lower respiratory tract infections, and emerging and re-emerging infections affecting sub-Saharan Africa (such as Ebola, yellow fever and COVID-19), in addition to HIV, TB, and malaria. EDCTP2 also supports all phases of clinical trials (I–IV) as well as medicinal product-focused implementation research.
The legal structure for implementing the EDCTP2 programme has also evolved from EDCTP1, with an EDCTP Association (under Dutch law) having been established in 2014 to allow EDCTP2 membership to be opened up to sub-Saharan African countries, thus ensuring a true European-African partnership. EDCTP2 receives funds from the European Union through the Horizon 2020 programme. EDCTP2 Participating States also make contributions (cash or in-kind) to activities aligned with EDCTP’s goals. EDCTP partners, including industry, product development partnerships, development cooperation organisations and research institutions, also make cash or in-kind contributions to EDCTP2 calls. Learn more about the funding of the EDCTP2 programme.
The Global Health EDCTP3 programme
On 19 November 2021, the European Commission announced the adoption of 10 European Partnerships set up between the European Union, Member States and/or the industry, including the Global Health EDCTP3 Partnership. According to the Council Regulation establishing the GH EDCTP3 Joint Undertaking under Horizon Europe, the Global Health EDCTP3 partnership is defined as a Joint Undertaking (based on Article 187 of the Treaty on the Functioning of the European Union). As an Article 187 Initiative, the Global Health EDCTP3 Joint Undertaking will be a partnership between two entities – the European Commission, representing the European Union, and the EDCTP Association, representing the governments of European and sub-Saharan African countries participating in the partnership (Participating States).
The Global Health EDCTP3 Joint Undertaking will support international research partnerships accelerating the clinical evaluation of drugs, vaccines and diagnostics for key infectious diseases affecting sub-Saharan Africa, as well as novel approaches for surveillance and control of emerging/re-emerging infections in the region and globally. It will also strengthen clinical research capacity in sub-Saharan Africa. Building on the two previous EDCTP programmes, the Global Health EDCTP3 Joint Undertaking will ensure that more people gain access to new medical interventions and help to protect regional and global health security. By 2030, it aims to have progressed to license at least two new health technologies tackling infectious diseases, and to have supported at least 100 research institutes in 30 countries to enable effective and rapid research response to develop health technologies against re-emerging epidemics.
The adoption of the Council Regulation was the official start of the Global Health EDCTP3 Joint Undertaking, which is currently at the set-up and implementation stage, including recruitment of staff, appointment of advisory bodies and adoption of work programmes. It is established until 31 December 2031. Please consult the Global Health EDCTP3 Joint Undertaking website for recent developments.
For more information, please read the Frequently asked questions.